MX2008012920A - Inhibidores de los canales de iones task-1 y task-3. - Google Patents
Inhibidores de los canales de iones task-1 y task-3.Info
- Publication number
- MX2008012920A MX2008012920A MX2008012920A MX2008012920A MX2008012920A MX 2008012920 A MX2008012920 A MX 2008012920A MX 2008012920 A MX2008012920 A MX 2008012920A MX 2008012920 A MX2008012920 A MX 2008012920A MX 2008012920 A MX2008012920 A MX 2008012920A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- cancer
- disease
- respiratory disorders
- task
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La invención se refiere al uso de inhibidores de Kv1.5 para producir un medicamento para la terapia o profilaxis de trastornos respiratorios, trastornos respiratorios relacionados con el sueño, apneas del sueño central y obstructivas, síndrome de la resistencia de vías aéreas superiores, respiración de Cheyne-Stokes, ronquido, impulso respiratorio central interrumpido, muerte infantil súbita, hipoxia y apnea post-operativas, trastornos respiratorios relacionados con la musculatura, trastornos respiratorios tras ventilación a largo plazo, trastornos respiratorios durante adaptación a la alta montaña, trastornos pulmonares agudos y crónicos con hipoxia e hipercapnia, trastornos neurodegenerativos, demencia, enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, trastornos cancerígenos, cáncer de mama, cáncer de pulmón, cáncer de colon y cáncer de próstata.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006019589A DE102006019589A1 (de) | 2006-04-27 | 2006-04-27 | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
DE102006049527A DE102006049527A1 (de) | 2006-10-20 | 2006-10-20 | Inhibitoren des TASK-1 und TASK-3 Ionenkanals |
PCT/EP2007/003293 WO2007124849A2 (en) | 2006-04-27 | 2007-04-13 | Inhibitors of the task-1 and task-3 ion channel |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008012920A true MX2008012920A (es) | 2008-10-15 |
Family
ID=38258824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008012920A MX2008012920A (es) | 2006-04-27 | 2007-04-13 | Inhibidores de los canales de iones task-1 y task-3. |
Country Status (27)
Country | Link |
---|---|
US (1) | US20090149496A1 (es) |
EP (1) | EP2012758A2 (es) |
JP (1) | JP5161871B2 (es) |
KR (1) | KR101390239B1 (es) |
CN (1) | CN101636154B (es) |
AR (1) | AR060822A1 (es) |
AU (1) | AU2007245891B2 (es) |
BR (1) | BRPI0710946A2 (es) |
CA (1) | CA2650391C (es) |
CO (1) | CO6140023A2 (es) |
CR (1) | CR10342A (es) |
DO (1) | DOP2007000083A (es) |
EC (1) | ECSP088847A (es) |
GT (1) | GT200800213A (es) |
HK (1) | HK1138183A1 (es) |
IL (1) | IL194868A (es) |
MA (1) | MA30357B1 (es) |
MX (1) | MX2008012920A (es) |
NO (1) | NO20084513L (es) |
NZ (1) | NZ572231A (es) |
PE (1) | PE20080061A1 (es) |
RU (1) | RU2436577C2 (es) |
SG (1) | SG163543A1 (es) |
TN (1) | TNSN08431A1 (es) |
TW (1) | TWI398432B (es) |
UY (1) | UY30313A1 (es) |
WO (1) | WO2007124849A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105130957A (zh) * | 2009-05-29 | 2015-12-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
KR20120016265A (ko) | 2009-06-03 | 2012-02-23 | 사노피-아벤티스 도이칠란트 게엠베하 | 2''-{[2-(4-메톡시-페닐)-아세틸아미노]-메틸}-비페닐-2-카르복실산 (2-피리딘-3-일-에틸)-아미드의 결정질 상 |
US8664425B2 (en) * | 2010-02-02 | 2014-03-04 | Honeywell International Inc. | Bluegreen fluorescent compounds |
WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
BR112014005583A2 (pt) | 2011-09-12 | 2017-03-21 | Sanofi Sa | 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm |
DK2755972T3 (en) | 2011-09-12 | 2016-01-25 | Sanofi Sa | INDANYL SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLE [4,3-C] PYRIDINES, THEIR USE AS MEDICINE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE |
WO2013037914A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
HUE028378T2 (hu) | 2011-09-16 | 2016-12-28 | Sanofi Sa | Helyettesített 4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridinek, gyógyszerként való alkalmazásuk, és az ezeket tartalmazó gyógyászati készítmények |
LT2809669T (lt) | 2012-02-03 | 2017-05-10 | Sanofi | Kondensuoti piroldikarboksamidai ir jų panaudojimas kaip vaistų |
CN104721832A (zh) * | 2013-12-18 | 2015-06-24 | 深圳先进技术研究院 | 携带编码光敏感离子通道蛋白基因的表达载体在制备调控呼吸节律药物中的应用 |
JP2018516230A (ja) * | 2015-03-18 | 2018-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティ | カリウムチャネルkcnk9を標的とする新規モノクローナル抗体阻害剤 |
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
JOP20190005A1 (ar) * | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
CN110325110B (zh) | 2016-11-10 | 2022-08-09 | 纽约州立大学研究基金会 | 用于气道阻塞的系统、方法和生物标记 |
CN110381934B (zh) * | 2016-12-20 | 2023-07-11 | 芝加哥大学 | 用于治疗睡眠呼吸障碍(sdb)的l-pag衍生物 |
EP3338764A1 (de) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
JOP20190148A1 (ar) * | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
JOP20190141A1 (ar) * | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
EP3338803A1 (de) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
EP3762368B1 (en) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11073429B2 (en) | 2018-09-24 | 2021-07-27 | Rosemount Inc. | Non-invasive process fluid temperature indication for high temperature applications |
MA54275A (fr) * | 2018-11-27 | 2022-03-02 | Bayer Ag | Procédé de fabrication de formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
DE19929076A1 (de) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
US6531495B1 (en) * | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
AU2001288518A1 (en) * | 2000-08-30 | 2002-03-13 | Primecyte, Inc. | Methods for treating tumors using sulfonyl compounds |
GB2372503A (en) * | 2000-10-19 | 2002-08-28 | Glaxo Group Ltd | Voltage-gated potassium channel polypeptides |
DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10060807A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10061876A1 (de) * | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10121002A1 (de) * | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
EP1667977A4 (en) * | 2003-09-23 | 2009-09-09 | Merck & Co Inc | Isoquinolinone POTASSIUM CHANNEL INHIBITORS |
DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
WO2006058905A1 (en) * | 2004-12-01 | 2006-06-08 | Devgen Nv | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY |
DE102005028845A1 (de) * | 2005-06-22 | 2006-12-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
-
2007
- 2007-04-13 AU AU2007245891A patent/AU2007245891B2/en not_active Ceased
- 2007-04-13 KR KR1020087026167A patent/KR101390239B1/ko not_active IP Right Cessation
- 2007-04-13 CN CN2007800146321A patent/CN101636154B/zh not_active Expired - Fee Related
- 2007-04-13 WO PCT/EP2007/003293 patent/WO2007124849A2/en active Application Filing
- 2007-04-13 MX MX2008012920A patent/MX2008012920A/es active IP Right Grant
- 2007-04-13 EP EP07724232A patent/EP2012758A2/en not_active Withdrawn
- 2007-04-13 JP JP2009506946A patent/JP5161871B2/ja not_active Expired - Fee Related
- 2007-04-13 RU RU2008146755/15A patent/RU2436577C2/ru not_active IP Right Cessation
- 2007-04-13 NZ NZ572231A patent/NZ572231A/en not_active IP Right Cessation
- 2007-04-13 CA CA2650391A patent/CA2650391C/en not_active Expired - Fee Related
- 2007-04-13 SG SG201004686-0A patent/SG163543A1/en unknown
- 2007-04-13 BR BRPI0710946-6A patent/BRPI0710946A2/pt not_active IP Right Cessation
- 2007-04-25 AR ARP070101797A patent/AR060822A1/es unknown
- 2007-04-25 DO DO2007000083A patent/DOP2007000083A/es unknown
- 2007-04-25 PE PE2007000515A patent/PE20080061A1/es not_active Application Discontinuation
- 2007-04-25 TW TW096114514A patent/TWI398432B/zh not_active IP Right Cessation
- 2007-04-27 UY UY30313A patent/UY30313A1/es unknown
-
2008
- 2008-10-06 CR CR10342A patent/CR10342A/es unknown
- 2008-10-10 GT GT200800213A patent/GT200800213A/es unknown
- 2008-10-15 CO CO08109803A patent/CO6140023A2/es unknown
- 2008-10-16 US US12/252,516 patent/US20090149496A1/en not_active Abandoned
- 2008-10-23 IL IL194868A patent/IL194868A/en not_active IP Right Cessation
- 2008-10-24 MA MA31332A patent/MA30357B1/fr unknown
- 2008-10-24 EC EC2008008847A patent/ECSP088847A/es unknown
- 2008-10-24 TN TNP2008000431A patent/TNSN08431A1/en unknown
- 2008-10-27 NO NO20084513A patent/NO20084513L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HK HK10103417.7A patent/HK1138183A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN08431A1 (en) | Inhibitors of the task-1 and task -3 ion channel | |
GEP20227366B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
PH12019501408A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
PH12018501235A1 (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | |
TN2020000021A1 (en) | Substituted diazahetero-bicyclic compounds and their use | |
PH12019501458A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
MX2021003428A (es) | Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño. | |
SA521422114B1 (ar) | عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة واستخدامها في علاج اضطراب التنفس task-1 و task-3، | |
WO2015061790A3 (en) | Genetically-associated chronic obstructive pulmonary disease treatment | |
UA98460C2 (ru) | Применение ингибиторов ионных task-1 i task-3 каналов | |
MX2009010805A (es) | Metodos y composiciones que comprenden desvenlafaxina o duloxetina para el tratamiento de trastornos de la respiracion relacionados con el sueño. | |
AU2022298632A9 (en) | Methods for treating obstructive sleep apnea | |
JP2010523662A5 (es) | ||
TH91927A (th) | สารยับยั้ง task-1 และ task-3 ไอออนแชนเนล | |
EP2763687A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC SYNDROME, OBSTRUCTIVE RESPIRATORY DISORDERS, CANCER AND RELATED DISEASES | |
McArdle et al. | D30 NOVEL SCREENING APPROACHES AND THERAPIES FOR SLEEP DISORDERED BREATHING: Study Of A Novel Automatic Positive Airway Pressure Algorithm For The Treatment Of Obstructive Sleep Apnea In Women | |
AU2006904770A0 (en) | Automatic Positive Airway Pressure Therapy through the nose or mouth for treatment of Sleep Apnea and other respiratory disorders | |
Ryan et al. | Effect of a Nasal Pillow on Compliance, Nasal Symptoms and Quality of Life in Patients with Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure Therapy. | |
UA35600U (ru) | Способ лечения хронического обструктивного заболевания легких | |
UA35671U (ru) | Способ лечения больных хроническим обструктивным заболеванием легких на фоне гипертонической болезни | |
UA65422U (ru) | Способ проведения ингаляционной терапии у новорожденных на искусственной вентиляции легких | |
CN302135101S (zh) | 睡眠时的呼吸确保用管 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |